Evidence map›Paper›PMID 37477094›Full record

ArticleTherapeutic advances in respiratory disease

Linkage of NAMPT promoter variants to eNAMPT secretion, plasma eNAMPT levels, and ARDS severity.

Heather Lynn, Xiaoguang Sun, Nancy G Casanova, Christian Bime, Vivian Reyes Hernon, Clayton Lanham, Radu C Oita, Nikolas Ramos, Belinda Sun, Dawn K Coletta and 4 more

Open access · goldAbstract read
In one paragraph

Article in Therapeutic advances in respiratory disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. eNAMPT Is a Novel DAMP and Therapeutic Target in Human and Murine Pulmonary Fibrosis.American journal of respiratory cell and molecular biology · 2025
    Article
  6. Article
  7. Article
  8. Anti-DAMP therapies for acute inflammation.Frontiers in immunology · 2025
    Review
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Heather LynnCollege of Medicine, University of Arizona Health Sciences, Tucson, AZ, USA.
Xiaoguang SunCollege of Medicine, University of Arizona Health Sciences, Tucson, AZ, USA.
Nancy G CasanovaCollege of Medicine, University of Arizona Health Sciences, Tucson, AZ, USA.
Christian BimeCollege of Medicine, University of Arizona Health Sciences, Tucson, AZ, USA.
Vivian Reyes HernonCollege of Medicine, University of Arizona Health Sciences, Tucson, AZ, USA.
Clayton LanhamCollege of Medicine, University of Arizona Health Sciences, Tucson, AZ, USA.
Radu C OitaCollege of Medicine, University of Arizona Health Sciences, Tucson, AZ, USA.
Nikolas RamosCollege of Medicine, University of Arizona Health Sciences, Tucson, AZ, USA.
Belinda SunCollege of Medicine, University of Arizona Health Sciences, Tucson, AZ, USA.
Dawn K ColettaCollege of Medicine, University of Arizona Health Sciences, Tucson, AZ, USA.
Sara M CampCollege of Medicine, University of Arizona Health Sciences, Tucson, AZ, USA.
Jason H KarnesCollege of Pharmacy, University of Arizona Health Sciences, Tucson, AZ, USA.
Nathan A EllisCollege of Medicine, University of Arizona Health Sciences, Tucson, AZ, USA.
Joe G N GarciaDr. Herbert A. Wertheim Professor of Inflammation Science, Director, Center for Inflammation Science and Systems Medicine, University of Florida Scripps Research Institute, Jupiter, FL 33458, USA.ORCID 0000-0002-6934-0420
University of Arizona · USScripps Research Institute · US

Funding

Structure-Function Analysis of nmMLCK in EC Barrier ResponsesP01HL126609 · NHLBI · UNIVERSITY OF FLORIDA · PI STEVEN M DUDEK · 2016 to 2026
$24.4M
Novel Involvement of NAMPT and TLR4 in PAH Vascular RemodelingR01HL141387 · NHLBI · UNIVERSITY OF FLORIDA · PI Joe G. N. Garcia, Ayako Makino · 2019 to 2026
$3.8M
NHLBI NIH HHS P01 HL126609NHLBI NIH HHS R01 HL141387NIH/NHLBI and DOD grants P01HL126609 (JGNG), P01HL134610 (JGNG), R01HL141387 (JGNG), K08HL141623 (CB), R21HL168142 (CB/JGNG), R56HL160907 (CB),                W81XWH2110472(JGNG), R42HL164300 (JGNG).
6 · The paper itself

Abstract

BACKGROUND AND

objectiveseNAMPT (extracellular nicotinamide phosphoribosyltransferase), a novel DAMP and TLR4 ligand, is a druggable ARDS therapeutic target with METHODS AND

designHuman lung endothelial cells (ECs) transfected with

resultsComparisons of minor allelic frequency (MAF) in both ARDS cohorts with the 1000 Human Genome Project revealed the G-1535A and C-948A SNPs to be significantly associated with ARDS in Blacks compared with controls and trended toward significance in non-Hispanic Whites. LPS-challenged and LPS/18% CS-challenged EC harboring the -1535G wild-type allele exhibited significantly increased

conclusion

Indexed as

Nicotinamide PhosphoribosyltransferaseRespiratory Distress SyndromeCytokinesEndothelial CellsHumansLipopolysaccharidesLungCytokinesLipopolysaccharidesNicotinamide Phosphoribosyltransferaseacute respiratory distress syndrome (ARDS)enzyme-linked immunosorbent assayextracellular nicotinamide phosphoribosyltransferase (eNAMPT)genotype–phenotypeluciferase reporter

Identifiers

PMID37477094
PMCPMC10363883
OpenAlexW4384924313

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.